Date: 2017-05-03
Type of
information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: Grunenthal (Germany) 23andMe (USA - CA)
Product:
Action
mechanism:
Disease: pain
Therapeutic
area: CNS diseases - Neurological diseases
Country: USA
Trial
details:
Latest
news:
- • On May 3, 2017, 23andMe and Grünenthal announced a joint study to better understand how genes influence pain. Together, they seek to enroll 20,000 participants from the U.S. The study will be one of the largest of its kind to combine data on genetics and response to pain, including a pain tolerance experiment.
- 23andMe will invite eligible genotyped customers who have consented to participate in the pain study to provide information about their experience with pain via online surveys designed by Grünenthal and 23andMe. In addition, participants will be asked to self-administer a well-established pain endurance test — the Cold Pressor Test — to determine pain tolerance. The combined data set of survey answers and genetic information will be studied by scientists from 23andMe and Grünenthal to learn more about the differences in how people experience pain, and how best to manage pain with more targeted treatments.
- The new 23andMe and Grünenthal study could shed more light on why individuals experience pain differently by understanding genetic factors associated with pain sensitivity, progression, severity, and response to treatments.
Is
general: Yes
